Peripheral artery disease (PAD) affects over 8 million Americans, causing leg pain, reduced walking ability, and increased risk of limb loss. EECP is used off-label for PAD, with published evidence showing improvements in ankle-brachial index, walking distance, and endothelial function.
EECP is FDA-cleared for cardiac conditions (angina, heart failure). Its use for PAD is off-label — legal and common in medicine, supported by published clinical evidence, but not yet part of the FDA-cleared labeling. Always consult your physician before starting any new therapy.
Peripheral artery disease is caused by the same underlying process as coronary artery disease — atherosclerosis, the buildup of plaque in artery walls. In PAD, the arteries supplying the legs become narrowed or blocked, reducing blood flow to the muscles and tissues of the lower extremities. The result is intermittent claudication (leg pain with walking), rest pain, and in severe cases, non-healing wounds and limb loss.
Because PAD and coronary artery disease share the same pathophysiology, many patients have both conditions simultaneously. EECP — developed for cardiac conditions — has a mechanism of action that extends to the peripheral circulation: it stimulates collateral vessel growth, improves endothelial function, and increases blood flow throughout the vascular system, not just in the coronary arteries.
Clinical studies have documented improvements in ankle-brachial index (ABI), walking distance, and quality of life in PAD patients treated with EECP. Many EECP providers who treat cardiac patients also offer EECP for PAD, particularly for patients who are not candidates for revascularization (angioplasty or bypass surgery).
EECP addresses PAD through four physiological mechanisms that improve peripheral circulation and vascular health.
EECP inflates cuffs on the calves, thighs, and buttocks during diastole, driving blood toward the heart and simultaneously increasing perfusion pressure in peripheral vessels. This augmented flow reaches the ischemic limb tissues that are deprived of adequate circulation in PAD.
Repeated EECP sessions trigger the release of vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF), promoting the development of new collateral blood vessels that bypass blocked or narrowed peripheral arteries — similar to the mechanism in coronary circulation.
PAD is characterized by endothelial dysfunction — impaired ability of blood vessel walls to dilate and regulate blood flow. EECP increases nitric oxide production, restoring endothelial function and improving the responsiveness of peripheral blood vessels to metabolic demand.
PAD is an inflammatory condition. EECP has been shown to reduce circulating inflammatory markers including C-reactive protein (CRP) and interleukin-6, which may slow the progression of atherosclerosis in both coronary and peripheral vessels.
PAD is classified by the Fontaine staging system. EECP is most appropriate for Stages I–III, with the strongest evidence for Stage II (intermittent claudication).
Atherosclerotic narrowing detected on imaging but no symptoms. EECP may be considered as part of a cardiovascular risk reduction program, particularly in patients who also have coronary artery disease.
Leg pain or cramping with walking that resolves with rest. This is the most common presentation and the population with the strongest evidence for EECP benefit. Improvements in walking distance and ABI have been documented in clinical studies.
Constant leg pain at rest, indicating critical limb ischemia. EECP may be considered as an adjunct therapy in patients who are not candidates for revascularization, though evidence is more limited for this advanced stage.
Advanced critical limb ischemia with non-healing wounds or gangrene. EECP is generally not appropriate as primary therapy at this stage; revascularization or amputation evaluation takes precedence. Some EECP centers have reported use as an adjunct for wound healing.
Published studies on EECP for PAD are smaller than the cardiac literature but consistently show improvements in peripheral vascular function and walking capacity.
Vascular Medicine
Pilot study of EECP in patients with symptomatic lower extremity PAD demonstrated significant improvements in ankle-brachial index (ABI), walking distance, and quality of life scores after a standard 35-session course.
Journal of Vascular Surgery
EECP improved endothelial function and reduced inflammatory markers in PAD patients, suggesting a systemic vascular benefit beyond the cardiac circulation — consistent with the known mechanism of nitric oxide upregulation.
Clinical Cardiology
Patients with both coronary artery disease and peripheral artery disease who underwent EECP showed improvements in both cardiac symptoms and peripheral circulation, supporting the systemic vascular benefit of EECP.
American Journal of Cardiology
EECP stimulates the release of VEGF and other angiogenic growth factors, promoting the development of collateral blood vessels. This mechanism — well-established in coronary circulation — is believed to extend to peripheral vascular beds, explaining the observed improvements in limb perfusion.
For a comprehensive review of EECP clinical evidence across all indications, visit the Clinical Evidence Library →
Not all EECP providers offer treatment for PAD. Use our directory to find providers in your state, then check their individual listing to see which conditions they treat. Our grading system rewards providers who treat the full range of indications.
FDA-cleared for chronic stable angina — the primary cardiac indication.
FDA-cleared for heart failure — mechanism, evidence, and who qualifies.
VA coverage, Medicare eligibility, and how veterans can access EECP.
Peer-reviewed research on EECP for 20+ conditions including neuropathy, ED, and Long COVID.